Angle PLC EIS/VCT Advance Assurance and Total Voting Rights (6454V)
July 24 2018 - 12:42PM
UK Regulatory
TIDMAGL
RNS Number : 6454V
Angle PLC
24 July 2018
For immediate release 24 July 2018
ANGLE plc ("the Company")
EIS/VCT ADVANCE ASSURANCE AND TOTAL VOTING RIGHTS
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that, further to the announcement
of 18 July 2018, the Company has now received confirmation from
HMRC that an investment in the Company will qualify for VCT tax
relief ("VCT Advanced Assurance").
Completion of the Fundraising is conditional on Admission of the
EIS/VCT Placing Shares becoming effective ("EIS/VCT Admission") and
Admission of the General Placing Shares and Subscription Shares
becoming effective ("General Admission").
Application has been made for the 25,400,000 New Ordinary Shares
to be admitted to trading on AIM. Subject to the Placing Agreement
not having been terminated in accordance with its terms, it is
anticipated that:
-- admission of the 8,400,000 EIS/VCT Placing Shares is expected
to occur at 8.00 a.m. on or around 31 July 2018; and
-- admission of the 15,443,282 General Placing Shares and
1,556,718 Subscription Shares is expected to occur at 8.00 a.m. on
or around 1 August 2018.
With effect from EIS/VCT Admission, the Company will have
125,486,522 Ordinary Shares in issue, with no Ordinary Shares held
in treasury. Shareholders may use this figure as the denominator by
which they are required to notify their interest in, or change to
their interest in, the Company under the Disclosure Guidance and
Transparency Rules.
With effect from General Admission, the Company will have
142,486,522 Ordinary Shares in issue, with no Ordinary Shares held
in treasury. Shareholders may use this figure as the denominator by
which they are required to notify their interest in, or change to
their interest in, the Company under the Disclosure Guidance and
Transparency Rules.
Capitalised terms not otherwise defined in this announcement
shall have the same meaning ascribed to such terms in the
announcement released on 25 June 2018 unless the context requires
otherwise.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave,
Simon Hicks, Max Bullen-Smith
Corporate Broking - Alice Lane, Nikita
Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
This announcement contains inside information.
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TVRPGUGCMUPRGQC
(END) Dow Jones Newswires
July 24, 2018 12:42 ET (16:42 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024